NTLA Intellia Therapeutics, Inc.

Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space.

This biotech has grabbed plenty of headlines recently.

Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.

Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. The FDA does not plan to convene an advisory committee, with review supported by positive Phase 3 data and multiple global designations. The FDA's Priority Review of lonvo-z for hereditary angioedema is a key regulatory event to weigh...

Intellia Therapeutics (NASDAQ:NTLA) executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company’s ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event. Chief Executive Officer

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement. The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing […]

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.

Intellia Therapeutics (NASDAQ:NTLA) shares rose 8% on Tuesday after the U. S.

Intellia Therapeutics (NTLA) stock is in focus after the company arranged a $400 million non dilutive senior secured term loan facility with OrbiMed to support lonvoguran ziclumeran, or lonvo z, development and launch plans. The financing news comes after a mixed period for Intellia Therapeutics. The share price is US$12.74, with a 30-day share price return of 16.13%, but the 3-year total shareholder return has declined 66.36% and the 5-year total shareholder return has declined 92.07%. Scan...

Intellia Therapeutics recently entered into a US$400 million non-dilutive senior secured term loan facility with OrbiMed, including a US$75 million initial draw and milestone-based tranches primarily linked to lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, with full details to follow in an SEC Form 8-K filing. This financing structure, which ties most of the available capital to lonvo-z development milestones, highlights how central that program has become to Intellia’s funding...

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H

Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs.

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.

Lonvo-z Phase III trial met primary endpoint with 87% attack reduction versus placebo.

Wolfspeed, BigBear.ai and Others Face Heavy Short-Seller Pressure

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

Moby summary of Intellia Therapeutics, Inc.'s Q2 2026 earnings call

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

On August 6, 2026, Intellia Therapeutics reported second-quarter results showing a net loss of US$106.63 million and basic and diluted loss per share of US$0.80, compared with a net loss of US$101.26 million and loss per share of US$0.98 a year earlier. Over the first six months of 2026, Intellia reduced its net loss to US$202.87 million from US$215.58 million, while cutting basic and diluted loss per share from US$2.08 to US$1.61, pointing to some improvement in loss per share despite...

Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis. Chief Executive O

Intellia reports positive Phase III data for LONVOSI, resumes NEXI trials with new HLA safety insights, and maintains cash runway into 2028.

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of +8.53% and -3.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.